Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
http://link.springer.com/content/pdf/10.1007/s11899-012-0147-9.pdf
Reference24 articles.
1. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044–50.
2. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49–53.
3. •• Hallek, M., Fischer, K., Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747): 1164–74. This study has established the standard of care therapy for previously untreated CLL patients.
4. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88.
5. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;1:110–118.
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ibrutinib Combined with Compound Realgar Natural Indigo Tablets for the Treatment of Relapsed and Refractory Hodgkin Lymphoma: A Case Report and Literature Review;Advances in Clinical Medicine;2024
2. Revisiting Reddy: A DLBCL Do-over;2023-11-22
3. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach;Cell Reports Medicine;2023-10
4. Pharmacologic Features of Drugs Targeting Bruton's Tyrosine Kinase (BTK);Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15
5. Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine;Chemical Society Reviews;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3